Article(id=1330225094435124115, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225010435796998, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.02.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1632240000000, receivedDateStr=2021-09-22, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795079976899, onlineDateStr=2026-11-19, pubDate=1644422400000, pubDateStr=2022-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795079976899, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795079976899, creator=13701087609, updateTime=1795079976899, updator=13701087609, issue=Issue{id=1330225010435796998, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='2', pageStart='109', pageEnd='209', issueExtLink='null', onlineDate='null', pubDate='1644422400000', pubDateStr='2022-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795079956873, creator='13701087609', updateTime=1795084674007, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330244795886318219, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225010435796998, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330244795886318220, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225010435796998, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=200, endPage=204, ext={EN=ArticleExt(id=1330225094636450708, articleId=1330225094435124115, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress of Loncastuximab tesirine-lpyl, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Loncastuximab tesirine-lpyl was approved by FDA on April 23, 2021. It is the first approved CD19 antibody coupled drug targeting pyrrolobenzodiazepine (PBD) dimer for the treatment of adult patients with recurrent or refractory large B-cell lymphoma who have received two or more systemic therapies. This paper mainly reviewed the clinical research progress of loncastuximab tesirine-lpyl in B-cell-derived malignant tumors, in order to provide a new reference for the clinical treatment of adult patients with recurrent or refractory large B-cell lymphoma.

, authors=Lu WANG1, Yan REN1, Ziwen DING1, Jingyan ZHANG2, Yiyun YUAN2, Junlong WANG2, *, Na NI1, *, authorsList=Lu WANG, Yan REN, Ziwen DING, Jingyan ZHANG, Yiyun YUAN, Junlong WANG, Na NI, authorCompany=null, correspAuthors=Junlong WANG, Na NI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330225094867137429, articleId=1330225094435124115, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=Loncastuximab tesirine-lpyl的临床研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

Loncastuximab tesirine-lpyl于2021年4月23日获得FDA加速批准上市,是首个获批的CD19靶向吡咯并苯二氮杂䓬(pyrrolobenzodiazepine,PBD)二聚体的抗体偶联药物,用于治疗已接受过两种或多种系统疗法的复发性/难治性大B细胞淋巴瘤成人患者。该文主要综述了loncastuximab tesirine-lpyl在B细胞来源的恶性肿瘤中的临床研究进展,为复发性/难治性大B细胞淋巴瘤成人患者三线及以上治疗提供新的用药参考。

, authors=汪璐1, 任燕1, 丁子文1, 张婧妍2, 袁宜耘2, 王俊龙2, *, 倪娜1, *, authorsList=汪璐, 任燕, 丁子文, 张婧妍, 袁宜耘, 王俊龙, 倪娜, authorCompany=null, correspAuthors=王俊龙, 倪娜, authorNote=

汪璐,硕士研究生,研究方向:抗肿瘤药物的临床药学研究。

, correspAuthorsNote=
王俊龙,硕士,研究方向:药物临床研究。
倪娜,副研究员,研究方向:抗肿瘤药物的临床药学研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=vFu0rCCoG2j+bg6UUkT/dQ==, magXml=AmsHS2xGQJAhMXxfx9N13A==, pdfUrl=null, pdf=bEfkoaL95g+IpMIevPwPag==, pdfFileSize=1714960, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=pZcYAifS3pls25JFbi+bzg==, mapNumber=null, fund=null)}, authors=[Author(id=1330225095227847581, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095307539359, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095227847581, language=EN, stringName=Lu WANG, firstName=Lu, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095374648224, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095227847581, language=CN, stringName=汪璐, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

汪璐,硕士研究生,研究方向:抗肿瘤药物的临床药学研究。

"}, bioImg=null, bioContent=

汪璐,硕士研究生,研究方向:抗肿瘤药物的临床药学研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225095433368482, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095504671652, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095433368482, language=EN, stringName=Yan REN, firstName=Yan, middleName=null, lastName=REN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095563391909, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095433368482, language=CN, stringName=任燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225095626306471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095697609641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095626306471, language=EN, stringName=Ziwen DING, firstName=Ziwen, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095756329898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095626306471, language=CN, stringName=丁子文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225095827633068, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095890547630, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095827633068, language=EN, stringName=Jingyan ZHANG, firstName=Jingyan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095966045103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095827633068, language=CN, stringName=张婧妍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095143961497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=2., ext=[AuthorCompanyExt(id=1330225095152350106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225095160738715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225096045736881, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225097635378100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225096045736881, language=EN, stringName=Yiyun YUAN, firstName=Yiyun, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225097702486965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225096045736881, language=CN, stringName=袁宜耘, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095143961497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=2., ext=[AuthorCompanyExt(id=1330225095152350106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225095160738715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225097777984439, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225097857676217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225097777984439, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225097949950906, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225097777984439, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095143961497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=2., ext=[AuthorCompanyExt(id=1330225095152350106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225095160738715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225098017059772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225098100945854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225098017059772, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225098168054719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225098017059772, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])])], keywords=[Keyword(id=1330225098348409792, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=EN, orderNo=1, keyword=CD19), Keyword(id=1330225098428101569, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=EN, orderNo=2, keyword=loncastuximab tesirine-lpyl), Keyword(id=1330225098524570563, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=EN, orderNo=3, keyword=ADC), Keyword(id=1330225098583290820, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=EN, orderNo=4, keyword=large B-cell lymphoma), Keyword(id=1330225098654593989, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=CN, orderNo=1, keyword=CD19), Keyword(id=1330225098725897158, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=CN, orderNo=2, keyword=Loncastuximab tesirine-lpyl), Keyword(id=1330225098805588935, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=CN, orderNo=3, keyword=抗体偶联药物), Keyword(id=1330225098876892104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, language=CN, orderNo=4, keyword=大B细胞淋巴瘤)], refs=[Reference(id=1330225098990138313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies[J]. Blood, 2018, 131(10): 1094-1105, articleTitle=null, refAbstract=null), Reference(id=1330225099061441482, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee A. Loncastuximab tesirine: first approval[J]. Drugs, 2021, 81(10): 1229-1233., articleTitle=null, refAbstract=null), Reference(id=1330225099128550347, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents[J]. Expert Opin Investig Drugs. 2011, 20(6): 733-744., articleTitle=null, refAbstract=null), Reference(id=1330225099191464908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma[J]. N Engl J Med, 2017, 377(13): 1250-1260., articleTitle=null, refAbstract=null), Reference(id=1330225099271156687, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma[J]. N Engl J Med, 2017, 377(14): 1331-1344., articleTitle=null, refAbstract=null), Reference(id=1330225099371819984, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Thielen FW, Büyükkaramikli NC, Riemsma R, et al. Obinutuzumab in combination with chemotherapy for the first-line treatment of patients with advanced follicular lymphoma: an evidence review group evaluation of the NICE single technology appraisal[J]. Pharmacoeconomics, 2019, 37(8): 975-984., articleTitle=null, refAbstract=null), Reference(id=1330225099497649105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967): 517-528., articleTitle=null, refAbstract=null), Reference(id=1330225099585729490, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond[J]. Leuk Lymphoma, 2014, 55(5): 999-1006., articleTitle=null, refAbstract=null), Reference(id=1330225099673809875, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9): 836-847., articleTitle=null, refAbstract=null), Reference(id=1330225099757695956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity[J]. Adv Exp Med Biol, 2005, 560: 125-139., articleTitle=null, refAbstract=null), Reference(id=1330225099837387733, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Tedder TF. CD19: a promising B cell target for rheumatoid arthritis[J]. Nat Rev Rheumatol, 2009, 5(10): 572-577., articleTitle=null, refAbstract=null), Reference(id=1330225099917079510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy[J]. Leuk Lymphoma, 1995, 18(5-6): 385-397., articleTitle=null, refAbstract=null), Reference(id=1330225099975799767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Hammer O. CD19 as an attractive target for antibody-based therapy[J]. MAbs, 2012, 4(5): 571-577., articleTitle=null, refAbstract=null), Reference(id=1330225100030325720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy[J]. Exp Hematol Oncol, 2012, 1(1): 36., articleTitle=null, refAbstract=null), Reference(id=1330225100084851673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Jabbour E, O'Brien S, Ravandi F, et al. Monoclonal antibodies in acute lymphoblastic leukemia[J]. Blood, 2015, 125(26): 4010-4016., articleTitle=null, refAbstract=null), Reference(id=1330225100143571930, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Tiberghien AC, Levy JN, Masterson LA, et al. Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload[J]. ACS Med Chem Lett, 2016, 7(11): 983-987., articleTitle=null, refAbstract=null), Reference(id=1330225100227458011, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Diamantis N, Banerji U. Antibody-drug conjugates: an emerging class of cancer treatment[J]. Br J Cancer, 2016, 114(4): 362-367., articleTitle=null, refAbstract=null), Reference(id=1330225100290372572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Gerber HP, Kung-Sutherland M, Stone I, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas[J]. Blood, 2009, 113(18): 4352-4361., articleTitle=null, refAbstract=null), Reference(id=1330225100357481437, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments[J]. Mabs, 2009, 1(3): 247-253., articleTitle=null, refAbstract=null), Reference(id=1330225100420395998, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Nademanee A, Sureda A, Stiff P, et al. Safety analysis of brentuximab vedotin from the phase III AETHERA trial in hodgkin lymphoma in the post-transplant consolidation setting[J]. Biol Blood Marrow Transplant, 2018, 24(11): 2354-2359., articleTitle=null, refAbstract=null), Reference(id=1330225100483310559, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open label, phase 1 study[J]. Lancet Oncol, 2017, 18(1): 42-51., articleTitle=null, refAbstract=null), Reference(id=1330225102135866336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Puzanov I, Lee W, Chen AP, et al. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors[J]. Clin Cancer Res, 2011, 17(11): 3794-3802., articleTitle=null, refAbstract=null), Reference(id=1330225102211363809, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Phillips T, Barr PM, Park SI, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma[J]. Invest New Drugs, 2018, 37(2): 297-306., articleTitle=null, refAbstract=null), Reference(id=1330225102286861282, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Stein EM, Walter RB, Erba HP, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia[J]. Blood, 2018, 131(4): 387-396., articleTitle=null, refAbstract=null), Reference(id=1330225102358164451, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Tiberghien AC, Howard PW, Goundry WRF, et al. An alternative focus for route design for the synthesis of antibody-drug conjugate payloads[J]. J Org Chem, 2019, 84(8): 4830-4836., articleTitle=null, refAbstract=null), Reference(id=1330225102442050532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Kahl BS, Hamadani M, Radford J, et al. A phase I study of adct-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed/refractory B-cell non-hodgkin lymphoma[J]. Clin Cancer Res, 2019, 25(23): 6986-6994., articleTitle=null, refAbstract=null), Reference(id=1330225102500770789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 790-800., articleTitle=null, refAbstract=null), Reference(id=1330225102588851174, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Depaus J, Wagner-Johnston N, Zinzani PL, et al. Clinical activity of loncastuximab tesirine plus ibrutinib in non-hodgkin lymphoma: updated lotis 3 phase 1 results[J]. Hematol Oncol, 2021, 39(s2): 325-327., articleTitle=null, refAbstract=null), Reference(id=1330225102660154343, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Jain N, Stock W, Zeidan A, et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Blood Adv, 2020, 4(3): 449-457., articleTitle=null, refAbstract=null), Reference(id=1330225102731457512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Carlo-Stella C, Linhares Y, Gandhi MD, et al. Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5[J]. Hematol Oncol, 2021, 39(s2): 7574., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)]), AuthorCompany(id=1330225095143961497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=2., ext=[AuthorCompanyExt(id=1330225095152350106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225095160738715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.02.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.02.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.02.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.02.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1644422400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
Loncastuximab tesirine-lpyl的临床研究进展
汪璐 1 , 任燕 1 , 丁子文 1 , 张婧妍 2 , 袁宜耘 2 , 王俊龙 2, * , 倪娜 1, *
世界临床药物 | 综述评论 2022,43(2): 200-204
收起
收藏切换
世界临床药物 |综述评论 2022 , 43 (2) : 200 -204
Loncastuximab tesirine-lpyl的临床研究进展
全屏
[Author(id=1330225095227847581, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095307539359, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095227847581, language=EN, stringName=Lu WANG, firstName=Lu, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095374648224, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095227847581, language=CN, stringName=汪璐, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio={"content":"

汪璐,硕士研究生,研究方向:抗肿瘤药物的临床药学研究。

"}, bioImg=null, bioContent=

汪璐,硕士研究生,研究方向:抗肿瘤药物的临床药学研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225095433368482, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095504671652, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095433368482, language=EN, stringName=Yan REN, firstName=Yan, middleName=null, lastName=REN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095563391909, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095433368482, language=CN, stringName=任燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225095626306471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095697609641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095626306471, language=EN, stringName=Ziwen DING, firstName=Ziwen, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095756329898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095626306471, language=CN, stringName=丁子文, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])]), Author(id=1330225095827633068, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225095890547630, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095827633068, language=EN, stringName=Jingyan ZHANG, firstName=Jingyan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225095966045103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225095827633068, language=CN, stringName=张婧妍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095143961497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=2., ext=[AuthorCompanyExt(id=1330225095152350106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225095160738715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225096045736881, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225097635378100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225096045736881, language=EN, stringName=Yiyun YUAN, firstName=Yiyun, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225097702486965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225096045736881, language=CN, stringName=袁宜耘, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095143961497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=2., ext=[AuthorCompanyExt(id=1330225095152350106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225095160738715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225097777984439, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225097857676217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225097777984439, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225097949950906, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225097777984439, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海瀛科隆医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095143961497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=2., ext=[AuthorCompanyExt(id=1330225095152350106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China), AuthorCompanyExt(id=1330225095160738715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095143961497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海瀛科隆医药开发有限公司,上海 200437)])]), Author(id=1330225098017059772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225098100945854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225098017059772, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225098168054719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, authorId=1330225098017059772, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院药物临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225095060075414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, xref=1., ext=[AuthorCompanyExt(id=1330225095068464023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1330225095076852632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225094435124115, companyId=1330225095060075414, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院药物临床研究中心,上海 200437)])])]
汪璐1, 任燕1, 丁子文1, 张婧妍2, 袁宜耘2, 王俊龙2, *, 倪娜1, *
作者信息
  • 1.中国医药工业研究总院药物临床研究中心,上海 200437
  • 2.上海瀛科隆医药开发有限公司,上海 200437
通讯作者:
王俊龙,硕士,研究方向:药物临床研究。
倪娜,副研究员,研究方向:抗肿瘤药物的临床药学研究。
作者简介:

汪璐,硕士研究生,研究方向:抗肿瘤药物的临床药学研究。

Clinical research progress of Loncastuximab tesirine-lpyl
Lu WANG1, Yan REN1, Ziwen DING1, Jingyan ZHANG2, Yiyun YUAN2, Junlong WANG2, *, Na NI1, *
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai Clinical Research Organization for Medicines, Shanghai 200437, China
出版时间: 2022-02-10 doi: 10.13683/j.wph.2022.02.017
文章导航
收藏切换

Loncastuximab tesirine-lpyl于2021年4月23日获得FDA加速批准上市,是首个获批的CD19靶向吡咯并苯二氮杂䓬(pyrrolobenzodiazepine,PBD)二聚体的抗体偶联药物,用于治疗已接受过两种或多种系统疗法的复发性/难治性大B细胞淋巴瘤成人患者。该文主要综述了loncastuximab tesirine-lpyl在B细胞来源的恶性肿瘤中的临床研究进展,为复发性/难治性大B细胞淋巴瘤成人患者三线及以上治疗提供新的用药参考。

CD19  /  Loncastuximab tesirine-lpyl  /  抗体偶联药物  /  大B细胞淋巴瘤

Loncastuximab tesirine-lpyl was approved by FDA on April 23, 2021. It is the first approved CD19 antibody coupled drug targeting pyrrolobenzodiazepine (PBD) dimer for the treatment of adult patients with recurrent or refractory large B-cell lymphoma who have received two or more systemic therapies. This paper mainly reviewed the clinical research progress of loncastuximab tesirine-lpyl in B-cell-derived malignant tumors, in order to provide a new reference for the clinical treatment of adult patients with recurrent or refractory large B-cell lymphoma.

CD19  /  loncastuximab tesirine-lpyl  /  ADC  /  large B-cell lymphoma
汪璐, 任燕, 丁子文, 张婧妍, 袁宜耘, 王俊龙, 倪娜. Loncastuximab tesirine-lpyl的临床研究进展. 世界临床药物, 2022 , 43 (2) : 200 -204 . DOI: 10.13683/j.wph.2022.02.017
Lu WANG, Yan REN, Ziwen DING, Jingyan ZHANG, Yiyun YUAN, Junlong WANG, Na NI. Clinical research progress of Loncastuximab tesirine-lpyl[J]. World Clinical Drug, 2022 , 43 (2) : 200 -204 . DOI: 10.13683/j.wph.2022.02.017

参考文献 引证文献
排序方式:
[1]
Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies[J]. Blood, 2018, 131(10): 1094-1105
[2]
Lee A. Loncastuximab tesirine: first approval[J]. Drugs, 2021, 81(10): 1229-1233.
[3]
Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents[J]. Expert Opin Investig Drugs. 2011, 20(6): 733-744.
[4]
Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma[J]. N Engl J Med, 2017, 377(13): 1250-1260.
[5]
Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma[J]. N Engl J Med, 2017, 377(14): 1331-1344.
[6]
Thielen FW, Büyükkaramikli NC, Riemsma R, et al. Obinutuzumab in combination with chemotherapy for the first-line treatment of patients with advanced follicular lymphoma: an evidence review group evaluation of the NICE single technology appraisal[J]. Pharmacoeconomics, 2019, 37(8): 975-984.
[7]
Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967): 517-528.
[8]
Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond[J]. Leuk Lymphoma, 2014, 55(5): 999-1006.
[9]
Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9): 836-847.
[10]
Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity[J]. Adv Exp Med Biol, 2005, 560: 125-139.
[11]
Tedder TF. CD19: a promising B cell target for rheumatoid arthritis[J]. Nat Rev Rheumatol, 2009, 5(10): 572-577.
[12]
Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy[J]. Leuk Lymphoma, 1995, 18(5-6): 385-397.
[13]
Hammer O. CD19 as an attractive target for antibody-based therapy[J]. MAbs, 2012, 4(5): 571-577.
[14]
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy[J]. Exp Hematol Oncol, 2012, 1(1): 36.
[15]
Jabbour E, O'Brien S, Ravandi F, et al. Monoclonal antibodies in acute lymphoblastic leukemia[J]. Blood, 2015, 125(26): 4010-4016.
[16]
Tiberghien AC, Levy JN, Masterson LA, et al. Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload[J]. ACS Med Chem Lett, 2016, 7(11): 983-987.
[17]
Diamantis N, Banerji U. Antibody-drug conjugates: an emerging class of cancer treatment[J]. Br J Cancer, 2016, 114(4): 362-367.
[18]
Gerber HP, Kung-Sutherland M, Stone I, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas[J]. Blood, 2009, 113(18): 4352-4361.
[19]
Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments[J]. Mabs, 2009, 1(3): 247-253.
[20]
Nademanee A, Sureda A, Stiff P, et al. Safety analysis of brentuximab vedotin from the phase III AETHERA trial in hodgkin lymphoma in the post-transplant consolidation setting[J]. Biol Blood Marrow Transplant, 2018, 24(11): 2354-2359.
[21]
Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open label, phase 1 study[J]. Lancet Oncol, 2017, 18(1): 42-51.
[22]
Puzanov I, Lee W, Chen AP, et al. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors[J]. Clin Cancer Res, 2011, 17(11): 3794-3802.
[23]
Phillips T, Barr PM, Park SI, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma[J]. Invest New Drugs, 2018, 37(2): 297-306.
[24]
Stein EM, Walter RB, Erba HP, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia[J]. Blood, 2018, 131(4): 387-396.
[25]
Tiberghien AC, Howard PW, Goundry WRF, et al. An alternative focus for route design for the synthesis of antibody-drug conjugate payloads[J]. J Org Chem, 2019, 84(8): 4830-4836.
[26]
Kahl BS, Hamadani M, Radford J, et al. A phase I study of adct-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed/refractory B-cell non-hodgkin lymphoma[J]. Clin Cancer Res, 2019, 25(23): 6986-6994.
[27]
Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 790-800.
[28]
Depaus J, Wagner-Johnston N, Zinzani PL, et al. Clinical activity of loncastuximab tesirine plus ibrutinib in non-hodgkin lymphoma: updated lotis 3 phase 1 results[J]. Hematol Oncol, 2021, 39(s2): 325-327.
[29]
Jain N, Stock W, Zeidan A, et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Blood Adv, 2020, 4(3): 449-457.
[30]
Carlo-Stella C, Linhares Y, Gandhi MD, et al. Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5[J]. Hematol Oncol, 2021, 39(s2): 7574.
2022年第43卷第2期
18
6
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.02.017
  • 接收时间:2021-09-22
  • 首发时间:2026-11-19
  • 出版时间:2022-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-09-22
基金
作者信息
    1.中国医药工业研究总院药物临床研究中心,上海 200437
    2.上海瀛科隆医药开发有限公司,上海 200437

通讯作者:

王俊龙,硕士,研究方向:药物临床研究。
倪娜,副研究员,研究方向:抗肿瘤药物的临床药学研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.02.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏